Here’s what I’d do about the GlaxoSmithKline share price right now

The GlaxoSmithKline share price is under attack. Far from being a disaster, this could be a wake-up call for the firm and its management.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE: GSK) share price has been one of the FTSE 100’s worst-performers over the past year.

Including dividends paid to investors, the stock has returned -13.5% over the past 12 months. Over the same time frame, the FTSE All-Share has added 28.6%. That means shares in the pharmaceutical giant have underperformed by 42% since the end of April last year. 

This has changed over the past two months. Since the beginning of March, the stock has returned 13%. The GlaxoSmithKline share price has been boosted by the revelation that giant activist hedge fund Elliott Management has taken a stake in the business

Should you invest £1,000 in Polymetal right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Polymetal made the list?

See the 6 stocks

As of yet, we don’t know Elliott’s intentions, but I think we’ll soon find out.

This firm can be incredibly aggressive. In 2012 it seized an Argentine Navy vessel crewed by more than 200 sailors when it was in Ghana as part of a 15-year battle over unpaid debts. The hedge fund ultimately received a payout of $2.4bn on the debt, multiplying its investment four times. 

While Elliott can be aggressive, it also has an excellent track record of improving company performance and achieving positive outcomes for shareholders. 

Shock attack 

The very fact that the hedge fund has become involved could be enough to shock Glaxo into action. Over the past few years, the company’s spending on research and development has dwindled. This lack of expenditure has hurt its drug pipeline. The organisation now has fewer drugs under development than significant peers such as AstraZeneca

Glaxo is also trying to spin off its consumer healthcare business. The decision to spin off this division was initially met with praise in the City. However, this split is taking longer and costing more than expected. 

The one redeeming feature of the GlaxoSmithKline share price over the past few years has been its dividend yield. At the time of writing, the stock supports a dividend yield of 5.9%. That’s nearly double the FTSE 100 average. 

Unfortunately, this payout is on shaky ground. It does not make much sense for the company to scrimp on research and development spending while returning so much cash to investors. Management has already warned that the dividend may be cut after the business is split.

The group’s debt is also expanding. It has risen to £21bn, more than double the level reported five years ago. 

GlaxoSmithKline share price risks 

All in all, there are a lot of risks overhanging GlaxoSmithKline shares, and the business faces plenty of challenges as well. 

However, I believe that the fundamentals of the firm are solid. As such, I would buy the stock today. I think Glaxo’s fundamentals are sound, but the company is struggling for direction. Elliott could help drive it down the right path. 

Of course, the hedge fund’s involvement does not guarantee that Glaxo will produce market-beating returns. The company could try to fight its new shareholder, which may end up being a costly battle with no winner. Therefore, I would only buy a starter position for my portfolio. I’d want to see each party’s battle plan before taking a full position. 

Should you buy Polymetal now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

The dividend yield on this FTSE 100 stock has jumped 50% in a year. Time to buy?

Jon Smith explains why the yield on a FTSE 100 share has risen sharply over the past year but details…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

AstraZeneca’s share price is down 20% from September, so is it time for me to buy?

AstraZeneca’s share price has fallen a long way this year, which could mean a bargain to be had, so I…

Read more »

Man smiling and working on laptop
Investing Articles

2 top gold ETFs to consider in May!

Buying a gold exchange traded fund this month is a great idea to consider as the precious metal targets new…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

3 dirt cheap FTSE 250 shares for May

I think these FTSE 250 shares could be among the London stock market's best bargains to consider following recent turbulence.

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

£500 to invest in an ISA each month? Here’s how to target a potential £60k+ second income!

A regular monthly investment in a Stocks and Shares ISA could build a huge passive income in retirement. Let me…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

£10,000 invested in Jet2 shares 1 year ago is now worth…

Jet2 shares jumped on Tuesday 29 April after a positive trading report boosted investor sentiment. Dr James Fox explores his…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

£10,000 invested in BT shares 5 years ago is now worth…

BT shares have shone over the past 12 months, and that’s a little painful for me to say, having touted…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

I think this could be the best investment opportunity on the FTSE 100

Like many FTSE 100 stocks, this one has been through the mill in 2025. However, it hasn’t recovered, potentially offering…

Read more »